Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGI 003 (R(+)-verapamil) in non‑constipation predominant irritable bowel syndrome
2004-002752-34Phase 2Completed
- Sponsor
- AGI Therapeutics plc
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing AGI 003 with Placebo (2 arms). Primary endpoints: Global responder rate (patient’s global impression), Relief of abdominal discomfort/pain and 1 more. Started Nov 2004; status: completed.
02
Drugs
dexverapamil
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2004-002752-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002752-34.